An iron-catalyzed cross-coupling between di(hetero)arylmanganese reagents and primary and secondary alkyl halides is reported. No rearrangement of secondary alkyl halides to unbranched products was observed in these C–C bond-forming reactions.
Cobalt-Catalyzed C(sp<sup>2</sup>)–C(sp<sup>3</sup>) Cross-Coupling Reactions of Diarylmanganese Reagents with Secondary Alkyl Iodides
作者:Maximilian S. Hofmayer、Jeffrey M. Hammann、Diana Haas、Paul Knochel
DOI:10.1021/acs.orglett.6b03349
日期:2016.12.16
diarylmanganese reagents with secondaryalkyliodides using the THF-soluble salt CoCl2·2LiCl, which leads to the cross-coupling products in up to 92% yield, is reported. High diastereoselectivities can be reached in these cross-couplings (dr up to 99:1). Remarkably, rearrangement of secondaryalkyliodides to unbranched products was not observed in these C–C forming reactions.
The development of a copper-catalyzed cross-coupling betweenprimary and secondary (pseudo)halides and bicyclopentyl Grignard reagents is reported. Highly strained bicyclopentanes can be cross-coupled with a large panel of primaryalkyl mesylates and secondary alkyl iodides. The catalytic system is simple and cheap, and the reaction is general and chemoselective.
Selective introduction of fluorine into molecules by the cleavage of inert C−H bonds is of central academic and synthetic interest, yet remains challenging. Given the central role of alcohols in organic chemistry as the most ubiquitous building blocks, a versatile and selectiveC(sp3)−H and C(sp2)−H fluorination of simple alcohols, enabled by novel designed exo‐directing groups, is described. C(sp2)−H
This application discloses novel pyrimidinyl pyridone derivatives according to Formula I,
wherein R
1
, R
2
, and R
3
are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also disclosed are compositions comprising the compound of Formula I and methods of treatment comprising administering a therapeutically effective amount of the compound of Formula I to a subject in need thereof.